Company Overview

Redefining the Discovery and Design of Therapeutic Antibodies

Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer.

Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients. Our discovery engine, Dynamic Precision Library, is driving Adagene’s pipeline of programs with potential to be first or best in class.

We have forged strategic partnerships with multiple reputable global companies. These partnerships leverage our technology in approaches at the vanguard of science, including safer precision-guided antibody-drug conjugates and transformative antibody design.

Founded and led by world-class leaders in antibody discovery and engineering, Adagene is well-positioned to address unmet needs in areas where other treatments have had little or no success.